Determinants of Low Bone Turnover in Type 2 Diabetes-the Role of PTH
Open Access
- 3 October 2022
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 111 (6) , 587-596
Abstract
Determinants of low bone turnover in type 2 diabetes (T2DM) are poorly understood. To investigate the relationship between markers of bone turnover, glycaemic control, disease duration and calciotropic hormones in T2DM we assessed baseline biochemical data from the DiabOS Study, a prospective multicenter observational cohort study. In a cross-sectional study-design data from 110 postmenopausal women and men aged 50–75 years diagnosed with T2DM for at least 3 years and 92 non-diabetic controls were evaluated. Biochemical markers of bone formation (N-terminal propeptide of type I procollagen [PINP]), bone-specific alkaline phosphatase [BAP]) and resorption (C-terminal cross-linking telopeptide of type I collagen [CTX]), measures of calcium homeostasis (intact parathormone [iPTH], 25-Hydroxyvitamin D, calcium, magnesium) and glycaemic control were assessed. After adjustment for age, gender and body mass index (BMI), patients with T2DM had lower serum levels of PINP (p < 0.001), CTX (p < 0.001), iPTH (p = 0.03) and magnesium (p < 0.001) compared to controls. Serum calcium, creatinine, 25-Hydroxyvitamin D and sclerostin did not differ between both groups. In multivariate linear regression analyses only serum iPTH remained an independent determinant of bone turnover markers in T2DM (PINP: p = 0.02; CTX: p < 0.001 and BAP: p < 0.01), whereas glycated haemoglobin (HbA1c), disease duration, age and BMI were not associated with bone turnover. In conclusion low bone turnover in T2DM is associated with low iPTH. The underlying mechanism remains to be elucidated.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_169407)
- SGED/SSED
- Roche Diagnostics
- University of Basel
This publication has 51 references indexed in Scilit:
- WNT signaling in bone homeostasis and disease: from human mutations to treatmentsNature Medicine, 2013
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With MetforminDiabetes Care, 2011
- Determinants of serum sclerostin in healthy pre- and postmenopausal womenJournal of Bone and Mineral Research, 2011
- Bone structure and turnover in type 2 diabetes mellitusOsteoporosis International, 2011
- Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2010
- High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesisBone, 2008
- SOST is a target gene for PTH in boneBone, 2005
- Calcium Homeostasis During Oral Glucose Load in Healthy WomenHormone and Metabolic Research, 1999
- Calcium Metabolism in Diabetes Mellitus: Effect of Improved Blood Glucose ControlDiabetic Medicine, 1993
- Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasisEuropean Journal of Clinical Investigation, 1982